USA flag logo/image

An Official Website of the United States Government

THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
3191
Program Year/Program:
1985 / SBIR
Agency Tracking Number:
3191
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
H. G. Pars Pharmaceutical Labo
763 Concord Avenue Cambridge, MA 02138
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1985
Title: THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR THE IMPROVEMENT OF THIS VERY IMPORTANT CLASS OF ANTIMICROBIALS.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE MODIFICATION OF -LACTAM ANTIBIOTICS CONTINUES TO BE A PROMISING MEANS FOR THE IMPROVEMENT OF THIS VERY IMPORTANT CLASS OF ANTIMICROBIALS. THE VARIED USEFUL ATTRIBUTES OF THE NEW OXACEPHALOSPORIN MOXALACTAM, NAMELY BROAD SPECTRUM OF ACTIVITY, FAVORABLE PHARMACOKINETIC PROFILE, AND STABILITY, PROMPTS US TO PROPOSE THE SYNTHESIS AND EVALUATION OF A RELATED OXACEPHALOSPORIN STRUCTURE. RECENTLY WE SYNTHESIZED A NOVEL TRICYCLIC OXACEPHALOSPORIN WHICH IS EXPECTED TO LEAD TO A SERIES OF COMPOUNDS FROM WHICH ANTIMICROBIAL ACTIVITY IS EXPECTED. WE NOW PROPOSE THE SYNTHESIS OF A SERIES OF THESE ANALOGS AND THEIR EVALUATION AGAINST A BROAD SPECTRUM OF BACTERIA. BASED UPON PRELIMINARY STRUCTURAL ANALYSIS, THIS NEW OXACEPHALOSPORIN APPEARS TO BE RELATED CLOSELY TO PENICILLINS, AND THEREFORE WE ANTICIPATE SIGNIFICANT GRAM-POSITIVE ACTIVITY IN ADDITION TO THE GRAM-NEGATIVE ACTIVITY CEPHALOSPORINS GENERALLY POSSESS. BY ANALOGY WITH MOXALACTAM, WE ANTICIPATE RESISTANCE TO BACTERIAL ENZYMATIC INACTIVATION, AN ATTRIBUTE WHICH IS INCREASINGLY IMPORTANT DUE TO WIDESPREAD RESISTANCE TO CURRENT ANTIBIOTICS. THIS PHASE I PROGRAM WILL PROVIDE THE BASIS FOR THE DEVELOPMENT OF STRUCTURES WITH IMPROVED ANTIBACTERIAL PROPERTIES AND WILL PROVIDE STRUCTURE ACTIVITY INFORMATION IN THE NEW CLASS OF OXACEPHALOSPORINS REPRESENTED BY MOXALACTAM.

Principal Investigator:

Eric p. duffy
PRINCIPAL INVESTIGATOR
6173542800

Business Contact:

Small Business Information at Submission:

H. G. Pars Pharmaceutical Labo
763d Concord Avenue Cambridge, MA 02138

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No